NasdaqGS - Delayed Quote USD

Tilray Brands, Inc. (TLRY)

Compare
1.7000 +0.0200 (+1.19%)
At close: 4:00 PM EDT
1.6900 -0.01 (-0.59%)
After hours: 5:38 PM EDT
Loading Chart for TLRY
DELL
  • Previous Close 1.6800
  • Open 1.6800
  • Bid 1.6800 x 26500
  • Ask 1.7100 x 20000
  • Day's Range 1.6600 - 1.7700
  • 52 Week Range 1.5000 - 2.9700
  • Volume 37,932,101
  • Avg. Volume 21,710,147
  • Market Cap (intraday) 1.488B
  • Beta (5Y Monthly) 2.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3300
  • Earnings Date Oct 10, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.32

Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Beverage Alcohol, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Hiball Energy, Redhook Brewery, Square Mile Cider, Widmer Brothers Brewing, Runner's High Brewing Company, Happy Flower, and Fresh Hemp Foods brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

www.tilray.com

2,650

Full Time Employees

May 31

Fiscal Year Ends

Recent News: TLRY

View More

Related Videos: TLRY

Performance Overview: TLRY

Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TLRY
26.09%
S&P 500
19.50%

1-Year Return

TLRY
25.11%
S&P 500
32.92%

3-Year Return

TLRY
84.75%
S&P 500
30.82%

5-Year Return

TLRY
92.93%
S&P 500
97.39%

Compare To: TLRY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TLRY

View More

Valuation Measures

Annual
As of 10/2/2024
  • Market Cap

    1.47B

  • Enterprise Value

    1.60B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.58

  • Price/Book (mrq)

    0.43

  • Enterprise Value/Revenue

    2.02

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.05%

  • Return on Assets (ttm)

    -1.41%

  • Return on Equity (ttm)

    -6.57%

  • Revenue (ttm)

    788.94M

  • Net Income Avi to Common (ttm)

    -244.98M

  • Diluted EPS (ttm)

    -0.3300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    260.52M

  • Total Debt/Equity (mrq)

    11.25%

  • Levered Free Cash Flow (ttm)

    11.7M

Research Analysis: TLRY

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 229.88M
Earnings -31.75M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

1.90
2.32 Average
1.7000 Current
4.00 High
 

Company Insights: TLRY

Research Reports: TLRY

View More
  • Tilray's Mix of Alcohol and Cannabis Businesses Fails to Generate Synergies or a Moat

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

    Rating
    Price Target
     
  • Tilray Earnings: Decent End to Fiscal 2024, but We See Limited Risk-Adjusted Upside

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

    Rating
    Price Target
     
  • Tilray's Mixed Portfolio Unlikely to Yield Synergies as Canadian Market Remains a Major Challenge

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

    Rating
    Price Target
     
  • Cannabis Shares Rally (Again) on Next Incremental Step to Federal Rescheduling

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

    Rating
    Price Target
     

People Also Watch